Table 4

Clinical features and response data for C&Ckine signatures based on bimodal C&Ckines

CategoryB1B2B3B4B5B6B7B8B9
All cases
    AML213820381189152
    MDS23181420481301
    Normal0000000019
B1B2B3B4B5B6B7B8Total
New AML
    No.17191631107814122
    AHD/secondary AML23.5%47.4%43.8%35.5%50.0%42.9%37.5%50.0%40.2%
    Favorable cytogenetics5.9%0.0%18.8%9.7%0.0%0.0%0.0%0.0%5.7%
    Intermediate cytogenetics41.2%52.6%25.0%51.6%50.0%71.4%62.5%21.4%45.1%
    Unfavorable cytogenetics52.9%47.4%56.3%38.7%50.0%28.6%37.5%78.6%49.2%
    FLT3 mutation25.0%15.4%0.0%12.5%28.3%50.0%33.0%22.0%18.8%
Treated new AML
    Treated17181628106712114
    CR76.5%33.3%68.8%71.4%50.0%50.0%28.6%58.3%58.8%
    Resistant23.5%38.9%25.0%25.0%20.0%50.0%71.4%25.0%30.7%
    Fail0.0%27.8%6.3%3.6%30.0%0.0%0.0%16.7%10.5%
    Relapse76.9%66.7%36.4%55.0%80.0%66.7%50.0%57.1%59.7%
    Alive23.5%5.6%18.8%25.0%10.0%16.7%14.3%25.0%18.4%
  • B1 through B8 indicates C&Ckine signature number based on bimodal analytes.

  • AHD/second indicates antecedent hematologic disorder ≥ 2 months or secondary AML; FLT3 mutation, positive test for an FLT-internal tandem duplication or D835 mutation; and CR, complete remission.